STOCK TITAN

Director at Palisade Bio (PALI) granted 336,904 RSUs with three-year vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Baltera Robert Jr. reported acquisition or exercise transactions in this Form 4 filing.

Palisade Bio director Robert Baltera Jr. received a grant of 336,904 Restricted Stock Units (RSUs) of common stock. Each RSU represents a right to one share and was awarded at $0.00 per share. The RSUs vest in three equal annual installments starting on June 10, 2026, contingent on his continued service, and his reported direct holdings after this grant are 336,904 shares.

Positive

  • None.

Negative

  • None.

Insights

Routine RSU grant increases director’s equity stake with three-year vesting.

Director Robert Baltera Jr. was granted 336,904 RSUs of Palisade Bio common stock at $0.00 per share. Form 4 code A and the footnote describe this as a grant or award, not an open‑market purchase or sale.

The RSUs vest in three equal annual installments beginning on June 10, 2026, subject to continuous service. This creates a multi‑year incentive tied to his ongoing role. Following the grant, his reported direct holdings total 336,904 shares, and no derivative positions remain in this filing.

Insider Baltera Robert Jr.
Role null
Type Security Shares Price Value
Grant/Award Common Stock 336,904 $0.00 --
Holdings After Transaction: Common Stock — 336,904 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 336,904 RSUs Grant of Restricted Stock Units on June 10, 2026 vesting schedule basis
Grant price $0.00 per share Reported transaction price for RSU award
Holdings after transaction 336,904 shares Total direct common stock holdings after RSU grant
Vesting schedule Three equal annual installments First installment on anniversary of June 10, 2026, subject to continuous service
Restricted Stock Unit ("RSU") financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
service-based vesting requirement financial
"The RSUs are subject to a service-based vesting requirement and shall vest"
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Baltera Robert Jr.

(Last)(First)(Middle)
C/O PALISADE BIO, INC.
4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)
DENVER COLORADO 80237

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A(1)336,904A(1)336,904D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.
/s/ Ryker Willie, Attorney-in-Fact for Robert Baltera06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Palisade Bio (PALI) report for Robert Baltera Jr.?

Palisade Bio reported that director Robert Baltera Jr. received a grant of 336,904 Restricted Stock Units (RSUs). The award was reported at $0.00 per share and classified as a grant or award acquisition, not an open-market purchase or sale, on the Form 4 filing.

How many Palisade Bio (PALI) shares are tied to the new RSU grant?

The new grant covers 336,904 Restricted Stock Units (RSUs), each representing one share of Palisade Bio common stock. After this grant, the Form 4 shows Robert Baltera Jr. directly holding 336,904 shares, reflecting the position associated with this award in the filing.

What is the vesting schedule for Robert Baltera Jr.’s Palisade Bio (PALI) RSUs?

The RSUs vest in three equal annual installments. The first installment vests on the anniversary of June 10, 2026, with the remaining two vesting annually thereafter, provided Robert Baltera Jr. continues to serve with Palisade Bio through each applicable vesting date.

Was cash paid for the Palisade Bio (PALI) RSU grant to Robert Baltera Jr.?

No cash payment is indicated for this award. The Form 4 reports the 336,904 Restricted Stock Units at a transaction price of $0.00 per share, consistent with an equity grant or award rather than a cash-funded purchase on the open market.

What are Robert Baltera Jr.’s Palisade Bio (PALI) holdings after this Form 4 transaction?

Following the reported RSU grant, the Form 4 lists Robert Baltera Jr.’s total direct holdings as 336,904 shares of Palisade Bio common stock. This figure reflects his position after the grant and does not show any remaining derivative securities in this filing.